SLC38A5 modulates ferroptosis to overcome gemcitabine resistance in pancreatic cancer
Bakris et al., Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: A randomized clinical trial
Weight loss is a common side effect of Ozempic
When it comes to reduction of weight-related issues like diabetes, heart disease risks and metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), bariatric surgery far outpaces GLP-1s in reduction, and often removal, of these risks
For those whose lives revolve around predictable routines, semaglutides weekly consistency often helps smooth hunger on workdays and during travel
GLP-1 Agonists: A New Frontier in Weight Loss Drugs GLP-1 agonists represent a novel approach to addressing obesity